Prognostic Value of 18F-FDG PET/CT Assessment After Radiotherapy of Squamous Cell Carcinoma of the Anus in Patients from the National Multicentric Cohort FFCD-ANABASE

This study aimed to evaluate the prognostic value of ¹⁸F-FDG PET/CT qualitative assessment in terms of recurrence-free survival (RFS), colostomy-free survival (CFS), and overall survival (OS) after radiation therapy (RT) of squamous cell carcinoma of the anus (SCCA). Secondary objectives were to evaluate the prognostic value of baseline and posttherapeutic quantitative ¹⁸F-FDG PET/CT parameters in terms of RFS, CFS, and OS. Methods: We included all consecutive patients from the French multicentric cohort FFCD-ANABASE who had undergone ¹⁸F-FDG PET/CT at baseline and 4–6 mo after RT or chemoradiotherapy for a localized SCCA. Qualitative assessments separated patients with complete metabolic response (CMR) and non-CMR. Quantitative parameters were measured on baseline and posttreatment ¹⁸F-FDG PET/CT. RFS, CFS, and OS were analyzed using the Kaplan–Meier method. Associations among qualitative assessments, quantitative parameters, and RFS, CFS, and OS were analyzed using univariate and multivariate Cox regression. Results: Among 1,015 patients treated between January 2015 and April 2020, 388 patients (300 women and 88 men) from 36 centers had undergone ¹⁸F-FDG PET/CT at diagnosis and after treatment. The median age was 65 y (range, 32–90 y); 147 patients (37.9%) had an early-stage tumor and 241 patients (62.1%) had a locally advanced-stage tumor; 59 patients (15.2%) received RT, and 329 (84.8%) received chemoradiotherapy. The median follow-up was 35.5 mo (95% CI, 32.8–36.6 mo). Patients with CMR had better 3-y RFS, CFS, and OS, at 84.2% (95% CI, 77.8%–88.9%), 84.7% (95% CI, 77.2%–89.3%), and 88.6% (95% CI, 82.5%–92.7%), respectively, than did non-CMR patients, at 42.1% (95% CI, 33.4%–50.6%), 47.9% (95% CI, 38.1%–56.8%), and 63.5 (95% CI, 53.2%–72.1%), respectively (P < 0.0001). Quantitative parameters were available for 154 patients from 3 centers. The following parameters were statistically significantly associated with 3-y RFS: baseline SUV_max (primitive tumor [T]) (hazard ratio [HR], 1.05 [95% CI, 1.01–1.1; P = 0.018]), SUV_peak (T) (HR, 1.09 [95% CI, 1.02–1.15; P = 0.007]), MTV 41% (T) (HR, 1.02 [95% CI, 1–1.03; P = 0.023]), MTV 41% (lymph node [N]) (HR, 1.06 [95% CI, 1.03–1.1; P < 0.001]), MTV 41% (T + N) (HR, 1.02 [95% CI, 1–1.03; P = 0.005]), and posttreatment SUV_max (HR, 1.21 [95% CI, 1.09–1.34; P < 0.001]). Conclusion: Treatment response assessed by ¹⁸F-FDG PET/CT after RT for SCCA has a significant prognostic value.¹⁸F-FDG PET/CT could be useful for adapting follow-up, especially for patients with locally advanced-stage tumors. Quantitative parameters could permit identification of patients with a worse prognosis but should be evaluated in further trials.